+1 (888) 794-0077
« Return

Virtual Tours Available Today

Explore our New Jersey facilities from wherever you are working, even the comfort of your own home.

Virtually tour our New Jersey facilities in Cranbury and Plainsboro to learn about our Bioanalytical and DMPK capabilities and instrumentation to support your drug discovery and development programs.

Let’s discuss how we can help you meet your goals!

Follow WuXi AppTec Laboratory Testing Division on LinkedIn for industry insights and program support.

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions – and has received ESG (Environment, Social and Governance) A Ratings from Morgan Stanley Capital International since 2019. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.”

For more information, please visit: https://labtesting.wuxiapptec.com/

Related Posts

Making the Most of the Golden Age of Small-Molecule Oncology Drugs

Making the Most of the Golden Age of Small-Molecule Oncology Drugs

Many of humanity’s most impactful pharmaceuticals, including penicillin and aspirin, are small-molecule drugs. Over time, the focus of research has shifted toward biologics, also known as large-molecule drugs. In 2016, for example, eight of the 10 best-selling drugs in the world were biologics. However, small-molecule drugs are now making a comeback as research advances and technology improves. One key area where small-molecule drugs are making the most significant impact is oncology. 

Evaluation of Immunogenicity for Oligonucleotide Drugs

Evaluation of Immunogenicity for Oligonucleotide Drugs

Drug research and development has evolved from focusing only on small molecule drugs into an era of advanced therapeutics. Among the pathogenic proteins related to human diseases, more than 80% belong to non-druggable targets. Meanwhile, most existing druggable targets are restricted by their structure and are difficult to develop.